18 December 2013
EMA/27446/2014
Restrictions on use of medicines containing ergot
derivatives
On 27 June 2013, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended
re
15.12.2017
Datei
PD
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
An agency of the European Union
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website
15.12.2017
Datei
PD
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
An agency of the European Union
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website
15.12.2017
Datei
PD
Annex III
Amendments to relevant sections of the Product Information
Note:
These amendments to the relevant sections of the Product Information are the outcome of the referral
procedure.
15.12.2017
Datei
PD
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
An agency of the European Union
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website
15.12.2017
Datei
PD
__
__
Pharmazeutische Unternehmer
Nachrichtlich: Stufenplanbeteiligte
Vancomycin-haltige Arzneimittel
Umsetzung des Durchführungsbeschlusses der EU-Kommiss
15.12.2017
Datei
PD
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
An agency of the European Union
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website
15.12.2017
Datei
PD
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
An agency of the European Union
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Send a question via our website
15.12.2017
Datei
PD
